May 1, 2017

TO: MUSC’s Industry Sponsored Research Collaborators

FROM: Kathleen T. Brady, MD, PhD
Vice President for Research
Medical University of South Carolina

Royce Sampson, MSN, RN, CRA
Director, Office of Clinical Research
Medical University of South Carolina

Re.: Prospective Reimbursement Analysis Requirement and Fees

Effective May 1, 2017, all new clinical research studies will be required to have a Prospective Reimbursement Analysis (PRA) review in order to be in compliance with federal billing regulations. The MUSC Office of Clinical Research (OCR) is responsible for ensuring enterprise-wide research billing compliance utilizing the Prospective Reimbursement Analysis (PRA) review process. A PRA review includes an objective determination of all billable services and funding sources as well as what can and cannot be billed to third party payers using the National Coverage Determination (NCDs) and the Local Coverage Determinations (LCDs) adopted by the Centers for Medicare and Medicaid Services (CMS), as well as clinical care guidelines. The PRA is used by the MUSC Health Revenue System as a guide to ensure items are correctly billed to insurance or the study/grant account. Industry-funded clinical research studies are assessed a $2,000 fee for this analysis. An OCR Amendment Fee of $500 is assessed for each study amendment with changes to billable items and services requiring a change to the PRA.

For more information, please contact the Office of Clinical Research at musc-ocr@musc.edu or at 843-792-7900. We look forward to working with the research community to address this important area of research compliance and to support increased efficiency and quality of research at MUSC.